Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonius de Boer

Showing results (231-240 of 282) with videos related to

Pageof 29
Sort By:
British Journal of Clinical Pharmacology|August 10, 2021
Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37 000 casesTalip E Eroglu, Carlo A Barcella, Marieke T Blom, et al.
Pharmacogenetics and Genomics|November 26, 2009
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantationAnkie Harmsze, Jochem W van Werkum, Heleen J Bouman, et al.
European Heart Journal|February 22, 2013
Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and communityAbdennasser Bardai, Ahmad S Amin, Marieke T Blom, et al.
BMC Medical Research Methodology|June 1, 2013
Phase IV non-inferiority trials and additional claims of benefitRosemarie D L C Bernabe, Grace Wangge, Mirjam J Knol, et al.
Pharmacogenetics|April 2, 2003
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypesAnke-Hilse Maitland-van der Zee, Bruno H Ch Stricker, Olaf H Klungel, et al.
Clinical Pharmacology and Therapeutics|April 30, 2022
Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' PerspectiveAmos J de Jong, Tessa I van Rijssel, Mira G P Zuidgeest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2011
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancerMaarten J Deenen, Jolien Tol, Artur M Burylo, et al.
Journal of Clinical Epidemiology|April 7, 2004
Comparison of two methodologies to analyze exposure to statins in an observational study on effectivenessAnke Hilse Maitland-van der Zee, Olaf H Klungel, Bruno H Ch Stricker, et al.
Current Drug Safety|November 13, 2013
CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysisJakob Starup-Linde, Oystein Karlstad, Stine Aistrup Eriksen, et al.
Pharmacoepidemiology and Drug Safety|June 8, 2011
Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapySimone R B M Eussen, Marcel L Bouvy, Cathy J M Rompelberg, et al.
Pageof 29

Showing results (231-240 of 282) with videos related to

Sort By:
Pageof 29
British Journal of Clinical Pharmacology|August 10, 2021
Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37 000 casesTalip E Eroglu, Carlo A Barcella, Marieke T Blom, et al.
Pharmacogenetics and Genomics|November 26, 2009
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantationAnkie Harmsze, Jochem W van Werkum, Heleen J Bouman, et al.
European Heart Journal|February 22, 2013
Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and communityAbdennasser Bardai, Ahmad S Amin, Marieke T Blom, et al.
BMC Medical Research Methodology|June 1, 2013
Phase IV non-inferiority trials and additional claims of benefitRosemarie D L C Bernabe, Grace Wangge, Mirjam J Knol, et al.
Pharmacogenetics|April 2, 2003
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypesAnke-Hilse Maitland-van der Zee, Bruno H Ch Stricker, Olaf H Klungel, et al.
Clinical Pharmacology and Therapeutics|April 30, 2022
Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' PerspectiveAmos J de Jong, Tessa I van Rijssel, Mira G P Zuidgeest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2011
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancerMaarten J Deenen, Jolien Tol, Artur M Burylo, et al.
Journal of Clinical Epidemiology|April 7, 2004
Comparison of two methodologies to analyze exposure to statins in an observational study on effectivenessAnke Hilse Maitland-van der Zee, Olaf H Klungel, Bruno H Ch Stricker, et al.
Current Drug Safety|November 13, 2013
CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysisJakob Starup-Linde, Oystein Karlstad, Stine Aistrup Eriksen, et al.
Pharmacoepidemiology and Drug Safety|June 8, 2011
Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapySimone R B M Eussen, Marcel L Bouvy, Cathy J M Rompelberg, et al.
Pageof 29